Palatin Technologies, Inc. (AMEX:PTN) is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems.

Palatin has a diverse pipeline of active development programs targeting melanocortin and natriuretic receptors, including acute hospital care products in the cardiovascular field for treatment of congestive heart failure, hard-to-control hypertension and for cardiac surgery organ protection, and products for sexual dysfunction, obesity and metabolic syndrome.